You are here

Article Text

Article menu
Download PDFPDF
Image of the moment
Amyloidoma mimicking multiple sclerosis
  1. Ide Smets1,2,
  2. Silvia Marino1,3,
  3. Gavin Giovannoni1,2
  1. 1 Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary Univerity London, London, UK
  2. 2 Department of Neurology, The Royal London Hospital, Barts Health NHS Trust, London, UK
  3. 3 Department of Cellular Pathology, The Royal London Hospital, Barts Health NHS Trust, London, UK
  1. Correspondence to Dr Ide Smets, Blizard Institute of Cell and Molecular Science, London E1 2AT, UK; i.smets{at}qmul.ac.uk

https://doi.org/10.1136/practneurol-2020-002855

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A 56-year-old woman developed optic neuritis in 2001 and progressive right-sided weakness dating from 2015. MR scan of the brain showed a solitary contrast-enhancing lesion in the left periventricular region and her cerebrospinal fluid (CSF) contained unmatched oligoclonal IgG bands. In 2017, she was diagnosed with multiple sclerosis (MS) and started disease-modifying treatment with glatiramer acetate. However, her symptoms progressed and she was referred to our centre for consideration of treatment escalation. On examination, she had a right haemiplegia with pronounced hypertonia, decreased left visual acuity and an afferent pupillary defect.

    Repeat MR scan of the brain showed that the lesion had grown, with persisting patchy but avid contrast-enhancement (figure 1A,B). Subsequent neuropathological examination (figure 1C …

    View Full Text

    Footnotes

    • Twitter @gavingiovannoni

    • Contributors IS, SM and GG have been involved in the clinical care of this patient, and reviewed the manuscript for intellectual content.

    • Funding IS ECTRIMS clinical fellowship Grant 2019.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned. Externally peer reviewed by Gillian Ingram, Swansea, UK.

    Linked Articles

    • Editors’ commentary
      Highlights from this issue
      Phil E M Smith Geraint N Fuller
      Practical Neurology 2021; 21 273-273 Published Online First: 23 Jul 2021. doi: 10.1136/practneurol-2021-003138